SlideShare a Scribd company logo
1 of 36
Download to read offline
Developments in medical device
regulation - 15 October 2015
John Skerritt
Deputy Secretary, Regulatory Services
Commonwealth Department of Health
This presentation
• Introducing the Devices Sponsor Information Day
• New Department of Health Regulatory Services Group and
changes to TGA structure
• Key facts and figures
• Expert Panel Review of Medicines and Medical Devices
Regulation
• International Collaboration
• Other changes made / anticipated to the IVD regulations
• Navigating the regulatory maze
• New Regulator Performance framework
The Devices Sponsor Information Day
• Today’s presentations are about the current regulatory
framework …although my presentation will look at emerging
trends and possible regulatory reforms
• Today is a great example of collaboration (in planning and
session delivery) between the Department of Health (TGA) and
four industry associations
• Two Streams
– Both - Conformity Assessment, GMP, Clinical Evidence (pre- and
post-market), Adverse events, Advertising and recalls
– Devices - Manufacturer evidence, ARTG inclusion, Audits, Lifecycle
– IVDs – Application processes, Technical File Reviews, Lifecycle
TGA’s role – part of the Department of Health
• Regulates therapeutic goods including prescription, over-the-
counter and complementary medicines, medical devices,
biologicals, blood and blood products
• Evaluates therapeutic goods before they are marketed and
monitors products once they are on the market
• Assesses the suitability of medicines and medical devices for
export
• Focuses on safety, efficacy and quality
• We do not make regulatory decisions based on value for money
or make decisions about which products receive Government
subsidy
Regulatory Services Group Structure
Medicines
Regulation
Medical
Devices and
Product Quality
Prescription
Medicines
Authorisation
Complementary
and OTC
Medicines
Pharmacovigilance
and Special
Access
Medical Devices
Laboratories
Manufacturing
Quality
Regulatory
Practice and
Support
Regulatory
Practice,
Education and
Compliance
Regulatory
Services and
Improvement
Regulatory
Engagement and
Planning
Office of
Chemical
Safety
Industrial Chemicals
(NICNAS)
AgVet Chemicals
Office of Gene
Technology
Regulator
Regulatory Practice
and Compliance
Evaluation
Scientific
Evaluation
Assistant
Minister for
Health
Regulatory Services Group
Deputy Secretary
Principal Medical
Adviser
Principal Legal and
Policy Adviser
Department of Health
Secretary
5
Medical Devices Branch
(Head: Dr Cheryl McRae)
Conformity Assessment (Dr Elizabeth McGrath)
Applications and Verification (Irina Tsyganova)
Devices Clinical (Dr Rona Hiam)
Devices Vigilance and Monitoring (Pamela Carter)
IVD Reforms (Michelle McNiven)
Business Improvement and Support (Rachel Croome)
Some key facts and figures
Did you know that as of 30 June 2015, there were:
47,458 medical devices on the ARTG
1,993 In vitro diagnostics on the ARTG
Compared with (only)….
15,425 prescription medicines ?
Conformity Assessment
Conformity
Assessment
Applications
Medical Devices IVDs
2012/13 2013/14 2014/15 2012/13 2013/14 2014/15
Received 190 195 141 34 40 19
Completed 188 245 161 18 41 40
- Successful 77 % 72 % 71 % 72 % 88 % 78 %
Main reason for rejections and applications withdrawn by the applicant is
errors in applications, the poor quality and/or unavailable data, including
clinical, engineering, biomaterials and quality management system
information
Inclusion in the ARTG
Applications
for Inclusion:
Medical Devices IVDs
2012/13 2013/14 2014/15 2012/13 2013/14 2014/15
Received
6500
(3700
assessed or
audited)
6300
(3400
assessed or
audited)
6100
(3600
assessed or
audited)
550 640 720
Completed 5850 (3050) 6700 (3800) 5900 (3400) 520 610 650
- Successfully
assessed or
audited
88 % 87 % 89 % 85 % 91 % 90 %
Applications for inclusion may be rejected or withdrawn due to incorrect
classification, or if information is not available such as clinical evidence
or information on conformity assessment procedures
Post Market reviews
Year
ARTG entries
reviewed
Reviews
completed
Cancelled by
sponsor
Cancelled by
TGA
2013 130 90 21 3
2014 226 168 34 13
Sponsor cancellations often due to device no longer being supplied, superseded,
manufacturer / sponsor changes.
TGA cancellations often due to non-response to s41JA requests for information,
inability to certify matters, non-compliance with class I auto-inclusion conditions.
Adverse event reports by class – 2014
245, 6%
1144, 26%
1757, 40%
480, 11%
35, 1%
291, 7%
7, 0% 38, 1% 77, 2% 253, 6% AIMD
Class III
Class IIb
Class IIa
Class 1
Sterile
Class 1
For Class II, III and AIMD devices this is roughly proportional to the
number of devices on the ARTG. Class I devices have few reports
despite representing around half of all devices on the ARTG.
Expert Panel Review of Medicine and
Medical Device Regulation
• Announced Oct 2014 to examine medicines and medical
devices regulation “to identify areas of unnecessary,
duplicative, or ineffective regulation and propose
opportunities to enhance the regulatory framework”
• First report on medicines and medical devices,
provided to government on 31 March and second report
on complementary medicines and advertising on 31 July
2015
• Devices stakeholder workshop run on 6 August 2015
• Next steps currently under consideration by the
Government
Overarching principles for regulation as
recommended by the Expert Panel
• Australia maintain the capacity to undertake
assessments of therapeutic goods for safety, quality and
efficacy
• The Australian Government, as a sovereign entity,
retain responsibility for approving the inclusion of
therapeutic goods in the ARTG
Some proposed initial reform bundles
• Reforms to registration of New Chemical Entities
• Reforms to generics and biosimilar medicines registration
• Risk based approaches to variations of medicines on the ARTG
• Reform to schemes for unapproved medicines and devices
(i.e. the Special Access and Authorised Prescriber Schemes)
• Establish criteria and mechanisms for expedited approval of
(very) novel medical devices
Review recommendations for Medical Devices
(also apply to IVDs)
• Multiple pathways are proposed for Class II, III, AIMD
devices and Class 2–4 IVD products:
– Conformity Assessment within Australia by either TGA or
a separate body designated by TGA; OR
– Utilisation of marketing approval for the device in an
overseas market where the device has been:
 Conformity Assessed by a body that has been designated by a
comparable overseas Designating Authority; or
 Approved by a comparable overseas regulatory authority
• Expedited approval process for devices in some
circumstances
Much further consultation will be needed as
implementation would be complex
• Few commercial conformity assessment bodies currently
exist in Australia
• International device/ IVD regulatory frameworks are quite
different to Australia and undergoing significant change, e.g.
– New European Device and IVD Regulations
– The US FDA system is very different - PMA vs 510(k), lack of clarity
around laboratory developed IVD tests
• Will need to define criteria and decision rights for expedited
approval of devices
• Approach to confidence building in notified bodies if there
are to be fewer application audits
Confidence building will require agreement
TGA accepts Conformity Assessment certification from Notified
Bodies, but highest risk devices currently have application audits
ARTG = 48,000
device entries
Highest risk
devices
(Class III and
AIMD) = 4,300
Manufactured
overseas=
4,250 (>98%)
Over 80% of highest risk
AIMDs/Class III devices are
included on the ARTG with
Conformity Assessment
certification from six Notified
Bodies:
• BSI (UK)
• TUV SUD (Germany)
• LNE/G-MED (France)
• Dekra (Netherlands)
• Lloyds LRQA (UK)
• Intertek (UK)
Other device / IVD recommendations
• Set binding timeframes for Conformity Assessment within
Australia or for device inclusion using an international approval
• Auto-inclusion of Class I devices to continue (unless if class
1 IVD selected for technical file review)
• Streamline access to medicines and medical devices
(including IVDs) that have not been approved in Australia
– Some SAS Category B applications could be subject to automatic
approval
– Online system for SAS notifications, approvals and reporting
Finally, a review of governance
arrangements was proposed by the Panel
• Comprehensive review of the
legislative framework to simplify its
structure and language
• Review and enhance TGA’s funding
model
• Alternative decision making
arrangements, including committees
• Greater collaboration with HTA
assessments (e.g. PBAC, MSAC)
IVD regulatory framework
• From 1990 to 2010 a limited number of
IVDs were regulated in Australia
including HIV and Hepatitis C virus
(HCV) tests
• In 2010 Australia introduced a more
comprehensive regulatory framework for
IVDs under the Therapeutic Goods
(Medical Devices) Regulations 2002
• New framework covers both commercial
and in-house (laboratory developed)
IVDs but not research use only or
analyte-specific reagents
Some current IVD regulatory reforms….
• Amended definition of a medical device to
include tests for predisposition and
susceptibility to a disease
• Modification to Classification for Class 3
IVDs that detect pathogens to remove
reference to National Notifiable Disease
Surveillance System list to instead use risk-
based classification principles (some IVDs may
be down classified to Class 2)
• Timeframe for submission of applications
for inclusion in the ARTG for commercial
IVDs had been extended but is now over !
International regulatory
collaboration now a formal
requirement by government
“ if a system, service or product has been approved under a
trusted international standard or risk assessment, then our
regulators should not impose any additional requirements
for approval in Australia, unless it can be demonstrated that
there is a good reason to do so…..
……. As an important first step, the Government will enable
Australian manufacturers of medical devices the option
of using EU certification in place of TGA certification.”
(media release 14 Oct 2014)
• Aims to accelerate international device
regulatory harmonisation and
convergence
• Established in 2012 to build on foundational
work of GHTF (Global Harmonization
Taskforce on Medical Devices)
• Members: Australia, Brazil, Canada, China,
EU, Japan, Russia and USA
• Asian Harmonization Working Party and
PAHO are affiliates and WHO and APEC are
observers
IMDRF Medical Device Single Audit Program
Pilot from Jan 2014 for 3 years to:
• Promote greater alignment of regulatory
approaches and technical requirements
• Develop a standard set of requirements for third
party organisations performing audits of
manufacturers’ QMS on behalf of regulators
• Standardise oversight practices and
procedures of participating regulators over third
party auditing organisations, and the auditing
organisations themselves
• Enable TGA resources to be focused on
problematic devices, manufacturers that are not
in compliance with regulations, and oversight of
third party auditors
IMDRF Medical Device Single Audit Program
Mid-pilot report released recently
• Third party Canadian auditing
organisation “registrars” assessed,
undergoing MDSAP recognition
requirements, comprehensive MDSAP QA
system established
• By end July 2015: several witnessed
audits conducted, 10 audits of
manufacturers conducted, 45
manufacturing sites requested participation
in the MDSAP program
• Initial progress is good – but greater
manufacturer participation will be vital to
success !
Other IMDRF projects
• Table of Contents pilot
– Will develop a comprehensive submission structure as an
international format for device premarket evaluation
– Greater uniformity and reduced regional divergence will reduce
burden on sponsors and increase efficiency of review
– TGA current seeking applications from sponsors to trial
• National Competent Authority Report review
– Facilitates exchange of post market safety information
• Software as a Medical Device
– Definitions document, Framework for Risk Categorization
– Harmonized vocabulary and considerations for manufacturers,
regulators and users to address unique challenges with SaMD
Other IMDRF projects
Completed
• Use of recognised Standards for devices to increase consistency
• Roadmap for UDI implementation
Recently initiated
• Integrating Patient Registries and Innovative Tools for Enhanced
Medical Device Evaluation and Tracking
• Medical device adverse event terminology
• Good regulatory review practice
Draft medical device clinical assessment
guidance documents
• Developed as drafts together with ASERNIPS (Australian Safety and
Efficacy Register of New Interventional Procedures – Surgical)
• These guidance documents do not intend to change regulatory
requirements but rather document the current situation
• Purpose is to clarify approaches to assessment of clinical
evidence for TGA evaluators, and help industry through providing
consistent advice
• No internationally accepted standards exist for clinical evidence for
many types of devices, so much interest from IMDRF members
• Consultation with PLAC, clinical craft groups and the device industry
will be the next step
Draft medical device clinical assessment
guidance documents: content
• General clinical evidence guidelines/ legislative requirements
– clinical dossiers, evaluation report and evaluation of clinical data
• Demonstrating substantial equivalence - guidance on use of
clinical evidence from predicate devices
• Guidance on specific high-risk device groups
– Total and partial joint prostheses
– Cardiovascular devices (that promote patency or functional flow)
– Electrical impulse generators
– Heart valve prostheses
– Supportive devices – meshes, patches and tissue adhesives
– Demonstrating MRI safety of active implantable medical devices
(e.g. cardiac pacemakers)
International inspection harmonisation
• About 90 % of overseas inspections are avoided
by TGA’s use of desktop clearances based on
information provided by other regulators
• International collaboration also includes:
– joint inspections with overseas partners
– Involvement in MDSAP
– shared inspection scheduling
– sharing of information, reports and manufacturer
information
– mutual recognition of codes and standards
Navigating the regulatory maze
• Australian regulatory guidelines for medical
devices – all 330 pages of it ….
• Currently developing simplified web linked
guidance….
• Device hotline: 1800 141 144 or
email devices@tga.gov.au
• SME workshops and contact points are
under consideration
Subscribe to the
TGA information
services to stay
up-to-date:
www.tga.gov.au
Receive information on:
• Safety alerts
• Recall actions
• Medical Devices Safety Update
• Consultations
• Publications
More specific information
• Therapeutic Goods Act 1989
(especially Chapter 4)
• Therapeutic Goods (Medical
Devices) Regulations 2002
• Australian Regulatory Guidelines for
Medical Devices
TGA Business Improvement Program
• Continue to enable electronic
submissions for device regulatory
processes
• Strengthened guidelines and
supporting information for sponsors
and manufacturers
• Centralised data repository – single
source of data a client relationship
management system
• New client self-service portal for
sponsors and manufacturers to
− check application status
− receive invoices
− respond to requests for information
Development underway of a new application form for
conformity assessment certificates
• Industry working group identified ways to improve the application form:
– See only what is applicable to your application
– Pre-population of information the TGA already has
– Guides the applicant with the information required
– Ability for TGA to push the form back to the client for more information
– Access to TGA issued CA certificates within the application
– Clear explanations and examples to assist with providing information
BIP Conformity Assessment Workflow tool
• Being further developed to remove problem issues
– Will support the CA process through: a CA Application eForm, workflow automation
for the administrative process, a CA Certificate Repository and Reporting Capability
• In 2016 work will commence on integrating other device business processes
into BIP, but will depend on changes to regulation that flow out of the MMDR
Regulator Performance Framework (from July 2015)
• Encourages regulators to have the minimum impact necessary to
achieve objectives and to effect positive ongoing and lasting change
• Six KPIs articulate the Government's expectations:
– Regulators do not unnecessarily impede the efficient operation of
regulated entities
– Communication with regulated entities is clear, targeted and effective
– Actions undertaken by regulators are proportionate to risk managed
– Compliance and monitoring approaches are streamlined and
coordinated
– Regulators are open and transparent in dealing with regulated entities
– Regulators actively contribute to continuous improvement of the
regulatory framework
• KPIs are supported by measures of good regulatory performance
Next steps for regulatory reform
• The MMDR recommendations (if accepted by Government) will
provide an opportunity to implement many welcome changes
• Government consideration of recommendations still to take place
• Once Government decisions on the proposed reforms are known,
implementation planning will be firmed up
• We need to agree a governance plan and timeline, resource
allocation, and the roles and responsibilities of different parts of TGA
• Reforms outside the Expert Panel Review continue (e.g. business
process reforms, in-house IVDs, Business Improvement Program)
• But today’s sessions are about the current regulatory framework !

More Related Content

What's hot

Devices Sponsor Information Day: 5 - Post-market - Adverse events and monitor...
Devices Sponsor Information Day: 5 - Post-market - Adverse events and monitor...Devices Sponsor Information Day: 5 - Post-market - Adverse events and monitor...
Devices Sponsor Information Day: 5 - Post-market - Adverse events and monitor...TGA Australia
 
Presentation: Clinical Evidence Guidelines
Presentation: Clinical Evidence GuidelinesPresentation: Clinical Evidence Guidelines
Presentation: Clinical Evidence GuidelinesTGA Australia
 
Devices Sponsor Information Day: 3A - Medical Devices - Manufacturer's eviden...
Devices Sponsor Information Day: 3A - Medical Devices - Manufacturer's eviden...Devices Sponsor Information Day: 3A - Medical Devices - Manufacturer's eviden...
Devices Sponsor Information Day: 3A - Medical Devices - Manufacturer's eviden...TGA Australia
 
TGA Presentation: TGA focus and wrap up - What we've done, and what we still ...
TGA Presentation: TGA focus and wrap up - What we've done, and what we still ...TGA Presentation: TGA focus and wrap up - What we've done, and what we still ...
TGA Presentation: TGA focus and wrap up - What we've done, and what we still ...TGA Australia
 
Devices Sponsor Information Day: 1 - Conformity Assessment
Devices Sponsor Information Day: 1 - Conformity AssessmentDevices Sponsor Information Day: 1 - Conformity Assessment
Devices Sponsor Information Day: 1 - Conformity AssessmentTGA Australia
 
Device Sponsor Information Day: Session 4B: Medical Devices (IVDs) - applicat...
Device Sponsor Information Day: Session 4B: Medical Devices (IVDs) - applicat...Device Sponsor Information Day: Session 4B: Medical Devices (IVDs) - applicat...
Device Sponsor Information Day: Session 4B: Medical Devices (IVDs) - applicat...TGA Australia
 
TGA presentation: Lifecycle of a Medical Device / IVD
TGA presentation: Lifecycle of a Medical Device / IVDTGA presentation: Lifecycle of a Medical Device / IVD
TGA presentation: Lifecycle of a Medical Device / IVDTGA Australia
 
Presentation: Recall of Therapeutic Goods
Presentation: Recall of Therapeutic GoodsPresentation: Recall of Therapeutic Goods
Presentation: Recall of Therapeutic GoodsTGA Australia
 
TGA presentation: AusMedtech, 24 May 2017
TGA presentation: AusMedtech, 24 May 2017 TGA presentation: AusMedtech, 24 May 2017
TGA presentation: AusMedtech, 24 May 2017 TGA Australia
 
Presentation: Medical Devices: how to stay included workshop - Post-market ro...
Presentation: Medical Devices: how to stay included workshop - Post-market ro...Presentation: Medical Devices: how to stay included workshop - Post-market ro...
Presentation: Medical Devices: how to stay included workshop - Post-market ro...TGA Australia
 
Presentation: Medical Devices: how to stay included workshop - Post-market re...
Presentation: Medical Devices: how to stay included workshop - Post-market re...Presentation: Medical Devices: how to stay included workshop - Post-market re...
Presentation: Medical Devices: how to stay included workshop - Post-market re...TGA Australia
 
TGA webinar: The Good Manufacturing Practice (GMP) Clearance Framework – an o...
TGA webinar: The Good Manufacturing Practice (GMP) Clearance Framework – an o...TGA webinar: The Good Manufacturing Practice (GMP) Clearance Framework – an o...
TGA webinar: The Good Manufacturing Practice (GMP) Clearance Framework – an o...TGA Australia
 
Presentation: The challenges of regulating direct to consumer digital medical...
Presentation: The challenges of regulating direct to consumer digital medical...Presentation: The challenges of regulating direct to consumer digital medical...
Presentation: The challenges of regulating direct to consumer digital medical...TGA Australia
 
Presentation: Updates from the Pharmacovigilance and Special Access Branch
Presentation: Updates from the Pharmacovigilance and Special Access BranchPresentation: Updates from the Pharmacovigilance and Special Access Branch
Presentation: Updates from the Pharmacovigilance and Special Access BranchTGA Australia
 
Presentation: Clinical Evidence Guidelines
Presentation: Clinical Evidence GuidelinesPresentation: Clinical Evidence Guidelines
Presentation: Clinical Evidence GuidelinesTGA Australia
 
Presentation: Proposed Reforms to the Regulation of Software, Including Softw...
Presentation: Proposed Reforms to the Regulation of Software, Including Softw...Presentation: Proposed Reforms to the Regulation of Software, Including Softw...
Presentation: Proposed Reforms to the Regulation of Software, Including Softw...TGA Australia
 
Update on software as a medical device (SaMD)
Update on software as a medical device (SaMD)Update on software as a medical device (SaMD)
Update on software as a medical device (SaMD)TGA Australia
 
Online Clinical Trial Notification (CTN)
Online Clinical Trial Notification (CTN)Online Clinical Trial Notification (CTN)
Online Clinical Trial Notification (CTN)TGA Australia
 
Presentation: Medical Devices: how to stay included workshop - Annual Reports
Presentation: Medical Devices: how to stay included workshop - Annual ReportsPresentation: Medical Devices: how to stay included workshop - Annual Reports
Presentation: Medical Devices: how to stay included workshop - Annual ReportsTGA Australia
 
Updates to Good Manufacturing Practices - Recent, current and future changes
Updates to Good Manufacturing Practices - Recent, current and future changesUpdates to Good Manufacturing Practices - Recent, current and future changes
Updates to Good Manufacturing Practices - Recent, current and future changesTGA Australia
 

What's hot (20)

Devices Sponsor Information Day: 5 - Post-market - Adverse events and monitor...
Devices Sponsor Information Day: 5 - Post-market - Adverse events and monitor...Devices Sponsor Information Day: 5 - Post-market - Adverse events and monitor...
Devices Sponsor Information Day: 5 - Post-market - Adverse events and monitor...
 
Presentation: Clinical Evidence Guidelines
Presentation: Clinical Evidence GuidelinesPresentation: Clinical Evidence Guidelines
Presentation: Clinical Evidence Guidelines
 
Devices Sponsor Information Day: 3A - Medical Devices - Manufacturer's eviden...
Devices Sponsor Information Day: 3A - Medical Devices - Manufacturer's eviden...Devices Sponsor Information Day: 3A - Medical Devices - Manufacturer's eviden...
Devices Sponsor Information Day: 3A - Medical Devices - Manufacturer's eviden...
 
TGA Presentation: TGA focus and wrap up - What we've done, and what we still ...
TGA Presentation: TGA focus and wrap up - What we've done, and what we still ...TGA Presentation: TGA focus and wrap up - What we've done, and what we still ...
TGA Presentation: TGA focus and wrap up - What we've done, and what we still ...
 
Devices Sponsor Information Day: 1 - Conformity Assessment
Devices Sponsor Information Day: 1 - Conformity AssessmentDevices Sponsor Information Day: 1 - Conformity Assessment
Devices Sponsor Information Day: 1 - Conformity Assessment
 
Device Sponsor Information Day: Session 4B: Medical Devices (IVDs) - applicat...
Device Sponsor Information Day: Session 4B: Medical Devices (IVDs) - applicat...Device Sponsor Information Day: Session 4B: Medical Devices (IVDs) - applicat...
Device Sponsor Information Day: Session 4B: Medical Devices (IVDs) - applicat...
 
TGA presentation: Lifecycle of a Medical Device / IVD
TGA presentation: Lifecycle of a Medical Device / IVDTGA presentation: Lifecycle of a Medical Device / IVD
TGA presentation: Lifecycle of a Medical Device / IVD
 
Presentation: Recall of Therapeutic Goods
Presentation: Recall of Therapeutic GoodsPresentation: Recall of Therapeutic Goods
Presentation: Recall of Therapeutic Goods
 
TGA presentation: AusMedtech, 24 May 2017
TGA presentation: AusMedtech, 24 May 2017 TGA presentation: AusMedtech, 24 May 2017
TGA presentation: AusMedtech, 24 May 2017
 
Presentation: Medical Devices: how to stay included workshop - Post-market ro...
Presentation: Medical Devices: how to stay included workshop - Post-market ro...Presentation: Medical Devices: how to stay included workshop - Post-market ro...
Presentation: Medical Devices: how to stay included workshop - Post-market ro...
 
Presentation: Medical Devices: how to stay included workshop - Post-market re...
Presentation: Medical Devices: how to stay included workshop - Post-market re...Presentation: Medical Devices: how to stay included workshop - Post-market re...
Presentation: Medical Devices: how to stay included workshop - Post-market re...
 
TGA webinar: The Good Manufacturing Practice (GMP) Clearance Framework – an o...
TGA webinar: The Good Manufacturing Practice (GMP) Clearance Framework – an o...TGA webinar: The Good Manufacturing Practice (GMP) Clearance Framework – an o...
TGA webinar: The Good Manufacturing Practice (GMP) Clearance Framework – an o...
 
Presentation: The challenges of regulating direct to consumer digital medical...
Presentation: The challenges of regulating direct to consumer digital medical...Presentation: The challenges of regulating direct to consumer digital medical...
Presentation: The challenges of regulating direct to consumer digital medical...
 
Presentation: Updates from the Pharmacovigilance and Special Access Branch
Presentation: Updates from the Pharmacovigilance and Special Access BranchPresentation: Updates from the Pharmacovigilance and Special Access Branch
Presentation: Updates from the Pharmacovigilance and Special Access Branch
 
Presentation: Clinical Evidence Guidelines
Presentation: Clinical Evidence GuidelinesPresentation: Clinical Evidence Guidelines
Presentation: Clinical Evidence Guidelines
 
Presentation: Proposed Reforms to the Regulation of Software, Including Softw...
Presentation: Proposed Reforms to the Regulation of Software, Including Softw...Presentation: Proposed Reforms to the Regulation of Software, Including Softw...
Presentation: Proposed Reforms to the Regulation of Software, Including Softw...
 
Update on software as a medical device (SaMD)
Update on software as a medical device (SaMD)Update on software as a medical device (SaMD)
Update on software as a medical device (SaMD)
 
Online Clinical Trial Notification (CTN)
Online Clinical Trial Notification (CTN)Online Clinical Trial Notification (CTN)
Online Clinical Trial Notification (CTN)
 
Presentation: Medical Devices: how to stay included workshop - Annual Reports
Presentation: Medical Devices: how to stay included workshop - Annual ReportsPresentation: Medical Devices: how to stay included workshop - Annual Reports
Presentation: Medical Devices: how to stay included workshop - Annual Reports
 
Updates to Good Manufacturing Practices - Recent, current and future changes
Updates to Good Manufacturing Practices - Recent, current and future changesUpdates to Good Manufacturing Practices - Recent, current and future changes
Updates to Good Manufacturing Practices - Recent, current and future changes
 

Viewers also liked

FDA Guidance on the Distribution fo Reprints
FDA Guidance on the Distribution fo ReprintsFDA Guidance on the Distribution fo Reprints
FDA Guidance on the Distribution fo ReprintsDickson Consulting
 
The ROI of Good Quality & Compliance
The ROI of Good Quality & ComplianceThe ROI of Good Quality & Compliance
The ROI of Good Quality & ComplianceMaetrics
 
The Impact of Directive 2007/47/EC
The Impact of Directive 2007/47/ECThe Impact of Directive 2007/47/EC
The Impact of Directive 2007/47/ECColin Rylett
 
PECB Webinar: Hands on medical devices risk assessment
PECB Webinar: Hands on medical devices risk assessmentPECB Webinar: Hands on medical devices risk assessment
PECB Webinar: Hands on medical devices risk assessmentPECB
 
Changing medical device regulations in Europe and the U.S.
Changing medical device regulations in Europe and the U.S.Changing medical device regulations in Europe and the U.S.
Changing medical device regulations in Europe and the U.S.Maetrics
 
FDA Expectations for Traceability in Device & Diagnostic Design
FDA Expectations for Traceability in Device & Diagnostic DesignFDA Expectations for Traceability in Device & Diagnostic Design
FDA Expectations for Traceability in Device & Diagnostic DesignSeapine Software
 
PECB Webinar: Overview of ISO 13485 - Medical Devices
PECB Webinar: Overview of ISO 13485 - Medical DevicesPECB Webinar: Overview of ISO 13485 - Medical Devices
PECB Webinar: Overview of ISO 13485 - Medical DevicesPECB
 
Medical Device Regulation
Medical Device RegulationMedical Device Regulation
Medical Device RegulationSam Nixon
 
EU Medical Device Regulation: Preparing for Disruptive (yet Incomplete) Regu...
EU Medical Device Regulation:  Preparing for Disruptive (yet Incomplete) Regu...EU Medical Device Regulation:  Preparing for Disruptive (yet Incomplete) Regu...
EU Medical Device Regulation: Preparing for Disruptive (yet Incomplete) Regu...YourEncoreInc
 
Addressing the challenge of the new European Union Medical Device Regulation
Addressing the challenge of the new European Union Medical Device RegulationAddressing the challenge of the new European Union Medical Device Regulation
Addressing the challenge of the new European Union Medical Device RegulationEY Belgium
 
MEDICAL DEVICE DEVELOPMENT_0327
MEDICAL DEVICE DEVELOPMENT_0327MEDICAL DEVICE DEVELOPMENT_0327
MEDICAL DEVICE DEVELOPMENT_0327Robert Stathopulos
 
Medical Product Development cycle
Medical Product Development cycleMedical Product Development cycle
Medical Product Development cyclemax hanafi
 
Good design practice for medical devices
Good design practice for medical devicesGood design practice for medical devices
Good design practice for medical devicesJakob Nielsen
 
Common Mistakes in the Medical Device Development Continuum
Common Mistakes in the Medical Device Development ContinuumCommon Mistakes in the Medical Device Development Continuum
Common Mistakes in the Medical Device Development ContinuumNAMSA
 
Understanding the New ISO 13485:2016 Revision
Understanding the New ISO 13485:2016 RevisionUnderstanding the New ISO 13485:2016 Revision
Understanding the New ISO 13485:2016 RevisionGreenlight Guru
 
Japan PMDA Medical Device Regulatory Approval Process
Japan PMDA Medical Device Regulatory Approval ProcessJapan PMDA Medical Device Regulatory Approval Process
Japan PMDA Medical Device Regulatory Approval ProcessEMERGO
 
Systems Engineering and Requirements Management in Medical Device Product Dev...
Systems Engineering and Requirements Management in Medical Device Product Dev...Systems Engineering and Requirements Management in Medical Device Product Dev...
Systems Engineering and Requirements Management in Medical Device Product Dev...UBMCanon
 
Design control FDA requirements
Design control FDA requirementsDesign control FDA requirements
Design control FDA requirementsLatvian University
 
Medical device development lifecycle
Medical device development lifecycleMedical device development lifecycle
Medical device development lifecycleTim Blair
 
How to Implement ISO 13485 Updates
How to Implement ISO 13485 UpdatesHow to Implement ISO 13485 Updates
How to Implement ISO 13485 UpdatesApril Bright
 

Viewers also liked (20)

FDA Guidance on the Distribution fo Reprints
FDA Guidance on the Distribution fo ReprintsFDA Guidance on the Distribution fo Reprints
FDA Guidance on the Distribution fo Reprints
 
The ROI of Good Quality & Compliance
The ROI of Good Quality & ComplianceThe ROI of Good Quality & Compliance
The ROI of Good Quality & Compliance
 
The Impact of Directive 2007/47/EC
The Impact of Directive 2007/47/ECThe Impact of Directive 2007/47/EC
The Impact of Directive 2007/47/EC
 
PECB Webinar: Hands on medical devices risk assessment
PECB Webinar: Hands on medical devices risk assessmentPECB Webinar: Hands on medical devices risk assessment
PECB Webinar: Hands on medical devices risk assessment
 
Changing medical device regulations in Europe and the U.S.
Changing medical device regulations in Europe and the U.S.Changing medical device regulations in Europe and the U.S.
Changing medical device regulations in Europe and the U.S.
 
FDA Expectations for Traceability in Device & Diagnostic Design
FDA Expectations for Traceability in Device & Diagnostic DesignFDA Expectations for Traceability in Device & Diagnostic Design
FDA Expectations for Traceability in Device & Diagnostic Design
 
PECB Webinar: Overview of ISO 13485 - Medical Devices
PECB Webinar: Overview of ISO 13485 - Medical DevicesPECB Webinar: Overview of ISO 13485 - Medical Devices
PECB Webinar: Overview of ISO 13485 - Medical Devices
 
Medical Device Regulation
Medical Device RegulationMedical Device Regulation
Medical Device Regulation
 
EU Medical Device Regulation: Preparing for Disruptive (yet Incomplete) Regu...
EU Medical Device Regulation:  Preparing for Disruptive (yet Incomplete) Regu...EU Medical Device Regulation:  Preparing for Disruptive (yet Incomplete) Regu...
EU Medical Device Regulation: Preparing for Disruptive (yet Incomplete) Regu...
 
Addressing the challenge of the new European Union Medical Device Regulation
Addressing the challenge of the new European Union Medical Device RegulationAddressing the challenge of the new European Union Medical Device Regulation
Addressing the challenge of the new European Union Medical Device Regulation
 
MEDICAL DEVICE DEVELOPMENT_0327
MEDICAL DEVICE DEVELOPMENT_0327MEDICAL DEVICE DEVELOPMENT_0327
MEDICAL DEVICE DEVELOPMENT_0327
 
Medical Product Development cycle
Medical Product Development cycleMedical Product Development cycle
Medical Product Development cycle
 
Good design practice for medical devices
Good design practice for medical devicesGood design practice for medical devices
Good design practice for medical devices
 
Common Mistakes in the Medical Device Development Continuum
Common Mistakes in the Medical Device Development ContinuumCommon Mistakes in the Medical Device Development Continuum
Common Mistakes in the Medical Device Development Continuum
 
Understanding the New ISO 13485:2016 Revision
Understanding the New ISO 13485:2016 RevisionUnderstanding the New ISO 13485:2016 Revision
Understanding the New ISO 13485:2016 Revision
 
Japan PMDA Medical Device Regulatory Approval Process
Japan PMDA Medical Device Regulatory Approval ProcessJapan PMDA Medical Device Regulatory Approval Process
Japan PMDA Medical Device Regulatory Approval Process
 
Systems Engineering and Requirements Management in Medical Device Product Dev...
Systems Engineering and Requirements Management in Medical Device Product Dev...Systems Engineering and Requirements Management in Medical Device Product Dev...
Systems Engineering and Requirements Management in Medical Device Product Dev...
 
Design control FDA requirements
Design control FDA requirementsDesign control FDA requirements
Design control FDA requirements
 
Medical device development lifecycle
Medical device development lifecycleMedical device development lifecycle
Medical device development lifecycle
 
How to Implement ISO 13485 Updates
How to Implement ISO 13485 UpdatesHow to Implement ISO 13485 Updates
How to Implement ISO 13485 Updates
 

Similar to Devices Sponsor Information Day: 0 - Developments in medical device regulation

Presentation: Regulatory affairs - The Australian and International landscape
Presentation: Regulatory affairs - The Australian and International landscapePresentation: Regulatory affairs - The Australian and International landscape
Presentation: Regulatory affairs - The Australian and International landscapeTGA Australia
 
2. 신규 체외진단법 도입에 따른 의료기기산업에 미치는 영향.pptx
2. 신규 체외진단법 도입에 따른 의료기기산업에 미치는 영향.pptx2. 신규 체외진단법 도입에 따른 의료기기산업에 미치는 영향.pptx
2. 신규 체외진단법 도입에 따른 의료기기산업에 미치는 영향.pptxDrSivakumarSelvaraj
 
Medicines and Medical Devices Regulation – current developments and future op...
Medicines and Medical Devices Regulation – current developments and future op...Medicines and Medical Devices Regulation – current developments and future op...
Medicines and Medical Devices Regulation – current developments and future op...TGA Australia
 
Stakeholders sensitization meeting
Stakeholders sensitization meetingStakeholders sensitization meeting
Stakeholders sensitization meetingPaulyne Wairimu
 
Presentation: Navigating regulation
Presentation: Navigating regulation Presentation: Navigating regulation
Presentation: Navigating regulation TGA Australia
 
China\'s Medical Device Regulatory Process
China\'s Medical Device Regulatory ProcessChina\'s Medical Device Regulatory Process
China\'s Medical Device Regulatory ProcessMedTech Review, LLC
 
The world of Regulatory convergence: an Australian reflection
The world of Regulatory convergence: an Australian reflectionThe world of Regulatory convergence: an Australian reflection
The world of Regulatory convergence: an Australian reflectionTGA Australia
 
The regulation of IVD medical devices
The regulation of IVD medical devicesThe regulation of IVD medical devices
The regulation of IVD medical devicesTGA Australia
 
Presentation: Therapeutic Goods Administration: An introduction to the work o...
Presentation: Therapeutic Goods Administration: An introduction to the work o...Presentation: Therapeutic Goods Administration: An introduction to the work o...
Presentation: Therapeutic Goods Administration: An introduction to the work o...TGA Australia
 
Presentation Trends in Australian and international regulation and regulatory...
Presentation Trends in Australian and international regulation and regulatory...Presentation Trends in Australian and international regulation and regulatory...
Presentation Trends in Australian and international regulation and regulatory...TGA Australia
 
International Overview & Future Medical Devices Regulations
International Overview & Future   Medical Devices RegulationsInternational Overview & Future   Medical Devices Regulations
International Overview & Future Medical Devices Regulationsmdbio2009
 
Regulatory Reform - an update
Regulatory Reform - an updateRegulatory Reform - an update
Regulatory Reform - an updateTGA Australia
 
TGA Presentation: TGA’s Role in Clinical Trials Regulation and Administration
TGA Presentation: TGA’s Role in Clinical Trials Regulation and AdministrationTGA Presentation: TGA’s Role in Clinical Trials Regulation and Administration
TGA Presentation: TGA’s Role in Clinical Trials Regulation and AdministrationTGA Australia
 
regulation of medical devices
regulation of medical devicesregulation of medical devices
regulation of medical devicesKeerthanaN20
 
Clinical trials - TGA role
Clinical trials - TGA roleClinical trials - TGA role
Clinical trials - TGA roleTGA Australia
 
Reg summary
Reg summaryReg summary
Reg summaryruyang89
 
Presentation: Earlier access to medicines and medical technologies and the MMDR
Presentation: Earlier access to medicines and medical technologies and the MMDRPresentation: Earlier access to medicines and medical technologies and the MMDR
Presentation: Earlier access to medicines and medical technologies and the MMDRTGA Australia
 
Presentation: Hints and Tips for Acceptance of your Prescription Medicines Su...
Presentation: Hints and Tips for Acceptance of your Prescription Medicines Su...Presentation: Hints and Tips for Acceptance of your Prescription Medicines Su...
Presentation: Hints and Tips for Acceptance of your Prescription Medicines Su...TGA Australia
 

Similar to Devices Sponsor Information Day: 0 - Developments in medical device regulation (20)

Presentation: Regulatory affairs - The Australian and International landscape
Presentation: Regulatory affairs - The Australian and International landscapePresentation: Regulatory affairs - The Australian and International landscape
Presentation: Regulatory affairs - The Australian and International landscape
 
2. 신규 체외진단법 도입에 따른 의료기기산업에 미치는 영향.pptx
2. 신규 체외진단법 도입에 따른 의료기기산업에 미치는 영향.pptx2. 신규 체외진단법 도입에 따른 의료기기산업에 미치는 영향.pptx
2. 신규 체외진단법 도입에 따른 의료기기산업에 미치는 영향.pptx
 
Medicines and Medical Devices Regulation – current developments and future op...
Medicines and Medical Devices Regulation – current developments and future op...Medicines and Medical Devices Regulation – current developments and future op...
Medicines and Medical Devices Regulation – current developments and future op...
 
Stakeholders sensitization meeting
Stakeholders sensitization meetingStakeholders sensitization meeting
Stakeholders sensitization meeting
 
medical-device-forum.pptx
medical-device-forum.pptxmedical-device-forum.pptx
medical-device-forum.pptx
 
Advamed MDR IVDR update
Advamed MDR IVDR updateAdvamed MDR IVDR update
Advamed MDR IVDR update
 
Presentation: Navigating regulation
Presentation: Navigating regulation Presentation: Navigating regulation
Presentation: Navigating regulation
 
China\'s Medical Device Regulatory Process
China\'s Medical Device Regulatory ProcessChina\'s Medical Device Regulatory Process
China\'s Medical Device Regulatory Process
 
The world of Regulatory convergence: an Australian reflection
The world of Regulatory convergence: an Australian reflectionThe world of Regulatory convergence: an Australian reflection
The world of Regulatory convergence: an Australian reflection
 
The regulation of IVD medical devices
The regulation of IVD medical devicesThe regulation of IVD medical devices
The regulation of IVD medical devices
 
Presentation: Therapeutic Goods Administration: An introduction to the work o...
Presentation: Therapeutic Goods Administration: An introduction to the work o...Presentation: Therapeutic Goods Administration: An introduction to the work o...
Presentation: Therapeutic Goods Administration: An introduction to the work o...
 
Presentation Trends in Australian and international regulation and regulatory...
Presentation Trends in Australian and international regulation and regulatory...Presentation Trends in Australian and international regulation and regulatory...
Presentation Trends in Australian and international regulation and regulatory...
 
International Overview & Future Medical Devices Regulations
International Overview & Future   Medical Devices RegulationsInternational Overview & Future   Medical Devices Regulations
International Overview & Future Medical Devices Regulations
 
Regulatory Reform - an update
Regulatory Reform - an updateRegulatory Reform - an update
Regulatory Reform - an update
 
TGA Presentation: TGA’s Role in Clinical Trials Regulation and Administration
TGA Presentation: TGA’s Role in Clinical Trials Regulation and AdministrationTGA Presentation: TGA’s Role in Clinical Trials Regulation and Administration
TGA Presentation: TGA’s Role in Clinical Trials Regulation and Administration
 
regulation of medical devices
regulation of medical devicesregulation of medical devices
regulation of medical devices
 
Clinical trials - TGA role
Clinical trials - TGA roleClinical trials - TGA role
Clinical trials - TGA role
 
Reg summary
Reg summaryReg summary
Reg summary
 
Presentation: Earlier access to medicines and medical technologies and the MMDR
Presentation: Earlier access to medicines and medical technologies and the MMDRPresentation: Earlier access to medicines and medical technologies and the MMDR
Presentation: Earlier access to medicines and medical technologies and the MMDR
 
Presentation: Hints and Tips for Acceptance of your Prescription Medicines Su...
Presentation: Hints and Tips for Acceptance of your Prescription Medicines Su...Presentation: Hints and Tips for Acceptance of your Prescription Medicines Su...
Presentation: Hints and Tips for Acceptance of your Prescription Medicines Su...
 

More from TGA Australia

Pharmacovigilance and complementary medicines - Regulatory requirements
Pharmacovigilance and complementary medicines - Regulatory requirementsPharmacovigilance and complementary medicines - Regulatory requirements
Pharmacovigilance and complementary medicines - Regulatory requirementsTGA Australia
 
The challenges of regulating direct to consumer digital medical devices
The challenges of regulating direct to consumer digital medical devicesThe challenges of regulating direct to consumer digital medical devices
The challenges of regulating direct to consumer digital medical devicesTGA Australia
 
Updates from the Pharmacovigilance and Special Access Branch
Updates from the Pharmacovigilance and Special Access Branch Updates from the Pharmacovigilance and Special Access Branch
Updates from the Pharmacovigilance and Special Access Branch TGA Australia
 
Consumer Medicine Information - Improving the CMI template
Consumer Medicine Information - Improving the CMI templateConsumer Medicine Information - Improving the CMI template
Consumer Medicine Information - Improving the CMI templateTGA Australia
 
Regulatory updates from the Complementary and OTC Medicines Branch - Listed m...
Regulatory updates from the Complementary and OTC Medicines Branch - Listed m...Regulatory updates from the Complementary and OTC Medicines Branch - Listed m...
Regulatory updates from the Complementary and OTC Medicines Branch - Listed m...TGA Australia
 
Improved electronic submission methodologies - Challenges and future state
Improved electronic submission methodologies - Challenges and future stateImproved electronic submission methodologies - Challenges and future state
Improved electronic submission methodologies - Challenges and future stateTGA Australia
 
Regulation, ethics and reimbursement of novel biological therapies in Austral...
Regulation, ethics and reimbursement of novel biological therapies in Austral...Regulation, ethics and reimbursement of novel biological therapies in Austral...
Regulation, ethics and reimbursement of novel biological therapies in Austral...TGA Australia
 
Good Clinical Practice Inspections - Consultation to introduce a pilot progra...
Good Clinical Practice Inspections - Consultation to introduce a pilot progra...Good Clinical Practice Inspections - Consultation to introduce a pilot progra...
Good Clinical Practice Inspections - Consultation to introduce a pilot progra...TGA Australia
 
Manufacturing Investigational Medicinal Products - Legislative and GMP requir...
Manufacturing Investigational Medicinal Products - Legislative and GMP requir...Manufacturing Investigational Medicinal Products - Legislative and GMP requir...
Manufacturing Investigational Medicinal Products - Legislative and GMP requir...TGA Australia
 
Update on regulatory reforms from the Scientific Evaluation Branch
Update on regulatory reforms from the Scientific Evaluation BranchUpdate on regulatory reforms from the Scientific Evaluation Branch
Update on regulatory reforms from the Scientific Evaluation BranchTGA Australia
 
Update on regulatory reforms from the Scientific Evaluation Branch
Update on regulatory reforms from the Scientific Evaluation BranchUpdate on regulatory reforms from the Scientific Evaluation Branch
Update on regulatory reforms from the Scientific Evaluation BranchTGA Australia
 
Reporting of Medicine Shortages
Reporting of Medicine ShortagesReporting of Medicine Shortages
Reporting of Medicine ShortagesTGA Australia
 
Regulatory updates from the TGA Medical Devices Branch - Part 1
Regulatory updates from the TGA Medical Devices Branch - Part 1Regulatory updates from the TGA Medical Devices Branch - Part 1
Regulatory updates from the TGA Medical Devices Branch - Part 1TGA Australia
 
Regulatory updates from the TGA Medical Devices Branch - Part 2
Regulatory updates from the TGA Medical Devices Branch - Part 2Regulatory updates from the TGA Medical Devices Branch - Part 2
Regulatory updates from the TGA Medical Devices Branch - Part 2TGA Australia
 
SME Assist: Help to navigate the regulatory maze
SME Assist: Help to navigate the regulatory mazeSME Assist: Help to navigate the regulatory maze
SME Assist: Help to navigate the regulatory mazeTGA Australia
 
TGA Presentation: Therapeutic Goods Advertising Code (No. 2) 2018
TGA Presentation: Therapeutic Goods Advertising Code (No. 2) 2018TGA Presentation: Therapeutic Goods Advertising Code (No. 2) 2018
TGA Presentation: Therapeutic Goods Advertising Code (No. 2) 2018TGA Australia
 
Webinar presentation: Consultation on reforms to the generic medicine market ...
Webinar presentation: Consultation on reforms to the generic medicine market ...Webinar presentation: Consultation on reforms to the generic medicine market ...
Webinar presentation: Consultation on reforms to the generic medicine market ...TGA Australia
 
Presentation: Software as a Medical Device: Regulatory insights and Q & A
Presentation: Software as a Medical Device: Regulatory insights and Q & APresentation: Software as a Medical Device: Regulatory insights and Q & A
Presentation: Software as a Medical Device: Regulatory insights and Q & ATGA Australia
 
Presentation: Implementing TGO 101
Presentation: Implementing TGO 101Presentation: Implementing TGO 101
Presentation: Implementing TGO 101TGA Australia
 
Presentation Therapeutic Goods (Standard for Tablets, Capsules and Pills) (TG...
Presentation Therapeutic Goods (Standard for Tablets, Capsules and Pills) (TG...Presentation Therapeutic Goods (Standard for Tablets, Capsules and Pills) (TG...
Presentation Therapeutic Goods (Standard for Tablets, Capsules and Pills) (TG...TGA Australia
 

More from TGA Australia (20)

Pharmacovigilance and complementary medicines - Regulatory requirements
Pharmacovigilance and complementary medicines - Regulatory requirementsPharmacovigilance and complementary medicines - Regulatory requirements
Pharmacovigilance and complementary medicines - Regulatory requirements
 
The challenges of regulating direct to consumer digital medical devices
The challenges of regulating direct to consumer digital medical devicesThe challenges of regulating direct to consumer digital medical devices
The challenges of regulating direct to consumer digital medical devices
 
Updates from the Pharmacovigilance and Special Access Branch
Updates from the Pharmacovigilance and Special Access Branch Updates from the Pharmacovigilance and Special Access Branch
Updates from the Pharmacovigilance and Special Access Branch
 
Consumer Medicine Information - Improving the CMI template
Consumer Medicine Information - Improving the CMI templateConsumer Medicine Information - Improving the CMI template
Consumer Medicine Information - Improving the CMI template
 
Regulatory updates from the Complementary and OTC Medicines Branch - Listed m...
Regulatory updates from the Complementary and OTC Medicines Branch - Listed m...Regulatory updates from the Complementary and OTC Medicines Branch - Listed m...
Regulatory updates from the Complementary and OTC Medicines Branch - Listed m...
 
Improved electronic submission methodologies - Challenges and future state
Improved electronic submission methodologies - Challenges and future stateImproved electronic submission methodologies - Challenges and future state
Improved electronic submission methodologies - Challenges and future state
 
Regulation, ethics and reimbursement of novel biological therapies in Austral...
Regulation, ethics and reimbursement of novel biological therapies in Austral...Regulation, ethics and reimbursement of novel biological therapies in Austral...
Regulation, ethics and reimbursement of novel biological therapies in Austral...
 
Good Clinical Practice Inspections - Consultation to introduce a pilot progra...
Good Clinical Practice Inspections - Consultation to introduce a pilot progra...Good Clinical Practice Inspections - Consultation to introduce a pilot progra...
Good Clinical Practice Inspections - Consultation to introduce a pilot progra...
 
Manufacturing Investigational Medicinal Products - Legislative and GMP requir...
Manufacturing Investigational Medicinal Products - Legislative and GMP requir...Manufacturing Investigational Medicinal Products - Legislative and GMP requir...
Manufacturing Investigational Medicinal Products - Legislative and GMP requir...
 
Update on regulatory reforms from the Scientific Evaluation Branch
Update on regulatory reforms from the Scientific Evaluation BranchUpdate on regulatory reforms from the Scientific Evaluation Branch
Update on regulatory reforms from the Scientific Evaluation Branch
 
Update on regulatory reforms from the Scientific Evaluation Branch
Update on regulatory reforms from the Scientific Evaluation BranchUpdate on regulatory reforms from the Scientific Evaluation Branch
Update on regulatory reforms from the Scientific Evaluation Branch
 
Reporting of Medicine Shortages
Reporting of Medicine ShortagesReporting of Medicine Shortages
Reporting of Medicine Shortages
 
Regulatory updates from the TGA Medical Devices Branch - Part 1
Regulatory updates from the TGA Medical Devices Branch - Part 1Regulatory updates from the TGA Medical Devices Branch - Part 1
Regulatory updates from the TGA Medical Devices Branch - Part 1
 
Regulatory updates from the TGA Medical Devices Branch - Part 2
Regulatory updates from the TGA Medical Devices Branch - Part 2Regulatory updates from the TGA Medical Devices Branch - Part 2
Regulatory updates from the TGA Medical Devices Branch - Part 2
 
SME Assist: Help to navigate the regulatory maze
SME Assist: Help to navigate the regulatory mazeSME Assist: Help to navigate the regulatory maze
SME Assist: Help to navigate the regulatory maze
 
TGA Presentation: Therapeutic Goods Advertising Code (No. 2) 2018
TGA Presentation: Therapeutic Goods Advertising Code (No. 2) 2018TGA Presentation: Therapeutic Goods Advertising Code (No. 2) 2018
TGA Presentation: Therapeutic Goods Advertising Code (No. 2) 2018
 
Webinar presentation: Consultation on reforms to the generic medicine market ...
Webinar presentation: Consultation on reforms to the generic medicine market ...Webinar presentation: Consultation on reforms to the generic medicine market ...
Webinar presentation: Consultation on reforms to the generic medicine market ...
 
Presentation: Software as a Medical Device: Regulatory insights and Q & A
Presentation: Software as a Medical Device: Regulatory insights and Q & APresentation: Software as a Medical Device: Regulatory insights and Q & A
Presentation: Software as a Medical Device: Regulatory insights and Q & A
 
Presentation: Implementing TGO 101
Presentation: Implementing TGO 101Presentation: Implementing TGO 101
Presentation: Implementing TGO 101
 
Presentation Therapeutic Goods (Standard for Tablets, Capsules and Pills) (TG...
Presentation Therapeutic Goods (Standard for Tablets, Capsules and Pills) (TG...Presentation Therapeutic Goods (Standard for Tablets, Capsules and Pills) (TG...
Presentation Therapeutic Goods (Standard for Tablets, Capsules and Pills) (TG...
 

Recently uploaded

Phytochemical Investigation of Drugs PDF.pdf
Phytochemical Investigation of Drugs PDF.pdfPhytochemical Investigation of Drugs PDF.pdf
Phytochemical Investigation of Drugs PDF.pdfDivya Kanojiya
 
Radiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxRadiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxDr. Dheeraj Kumar
 
Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!ibtesaam huma
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdfDolisha Warbi
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...sdateam0
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptxBibekananda shah
 
L1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptx
L1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptxL1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptx
L1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptxDr Bilal Natiq
 
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurMETHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurNavdeep Kaur
 
Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfDivya Kanojiya
 
Culture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptxCulture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptxDr. Dheeraj Kumar
 
Valproic Acid. (VPA). Antiseizure medication
Valproic Acid.  (VPA). Antiseizure medicationValproic Acid.  (VPA). Antiseizure medication
Valproic Acid. (VPA). Antiseizure medicationMohamadAlhes
 
Tans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxTans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxKezaiah S
 
Nutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience ClassNutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience Classmanuelazg2001
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfSasikiranMarri
 
epilepsy and status epilepticus for undergraduate.pptx
epilepsy and status epilepticus  for undergraduate.pptxepilepsy and status epilepticus  for undergraduate.pptx
epilepsy and status epilepticus for undergraduate.pptxMohamed Rizk Khodair
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiGoogle
 
Informed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxInformed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxSasikiranMarri
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners
 
Screening for colorectal cancer AAU.pptx
Screening for colorectal cancer AAU.pptxScreening for colorectal cancer AAU.pptx
Screening for colorectal cancer AAU.pptxtadehabte
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisGolden Helix
 

Recently uploaded (20)

Phytochemical Investigation of Drugs PDF.pdf
Phytochemical Investigation of Drugs PDF.pdfPhytochemical Investigation of Drugs PDF.pdf
Phytochemical Investigation of Drugs PDF.pdf
 
Radiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxRadiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptx
 
Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
 
L1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptx
L1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptxL1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptx
L1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptx
 
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurMETHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
 
Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdf
 
Culture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptxCulture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptx
 
Valproic Acid. (VPA). Antiseizure medication
Valproic Acid.  (VPA). Antiseizure medicationValproic Acid.  (VPA). Antiseizure medication
Valproic Acid. (VPA). Antiseizure medication
 
Tans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxTans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptx
 
Nutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience ClassNutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience Class
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdf
 
epilepsy and status epilepticus for undergraduate.pptx
epilepsy and status epilepticus  for undergraduate.pptxepilepsy and status epilepticus  for undergraduate.pptx
epilepsy and status epilepticus for undergraduate.pptx
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali Rai
 
Informed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxInformed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptx
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
 
Screening for colorectal cancer AAU.pptx
Screening for colorectal cancer AAU.pptxScreening for colorectal cancer AAU.pptx
Screening for colorectal cancer AAU.pptx
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
 

Devices Sponsor Information Day: 0 - Developments in medical device regulation

  • 1. Developments in medical device regulation - 15 October 2015 John Skerritt Deputy Secretary, Regulatory Services Commonwealth Department of Health
  • 2. This presentation • Introducing the Devices Sponsor Information Day • New Department of Health Regulatory Services Group and changes to TGA structure • Key facts and figures • Expert Panel Review of Medicines and Medical Devices Regulation • International Collaboration • Other changes made / anticipated to the IVD regulations • Navigating the regulatory maze • New Regulator Performance framework
  • 3. The Devices Sponsor Information Day • Today’s presentations are about the current regulatory framework …although my presentation will look at emerging trends and possible regulatory reforms • Today is a great example of collaboration (in planning and session delivery) between the Department of Health (TGA) and four industry associations • Two Streams – Both - Conformity Assessment, GMP, Clinical Evidence (pre- and post-market), Adverse events, Advertising and recalls – Devices - Manufacturer evidence, ARTG inclusion, Audits, Lifecycle – IVDs – Application processes, Technical File Reviews, Lifecycle
  • 4. TGA’s role – part of the Department of Health • Regulates therapeutic goods including prescription, over-the- counter and complementary medicines, medical devices, biologicals, blood and blood products • Evaluates therapeutic goods before they are marketed and monitors products once they are on the market • Assesses the suitability of medicines and medical devices for export • Focuses on safety, efficacy and quality • We do not make regulatory decisions based on value for money or make decisions about which products receive Government subsidy
  • 5. Regulatory Services Group Structure Medicines Regulation Medical Devices and Product Quality Prescription Medicines Authorisation Complementary and OTC Medicines Pharmacovigilance and Special Access Medical Devices Laboratories Manufacturing Quality Regulatory Practice and Support Regulatory Practice, Education and Compliance Regulatory Services and Improvement Regulatory Engagement and Planning Office of Chemical Safety Industrial Chemicals (NICNAS) AgVet Chemicals Office of Gene Technology Regulator Regulatory Practice and Compliance Evaluation Scientific Evaluation Assistant Minister for Health Regulatory Services Group Deputy Secretary Principal Medical Adviser Principal Legal and Policy Adviser Department of Health Secretary 5
  • 6. Medical Devices Branch (Head: Dr Cheryl McRae) Conformity Assessment (Dr Elizabeth McGrath) Applications and Verification (Irina Tsyganova) Devices Clinical (Dr Rona Hiam) Devices Vigilance and Monitoring (Pamela Carter) IVD Reforms (Michelle McNiven) Business Improvement and Support (Rachel Croome)
  • 7. Some key facts and figures Did you know that as of 30 June 2015, there were: 47,458 medical devices on the ARTG 1,993 In vitro diagnostics on the ARTG Compared with (only)…. 15,425 prescription medicines ?
  • 8. Conformity Assessment Conformity Assessment Applications Medical Devices IVDs 2012/13 2013/14 2014/15 2012/13 2013/14 2014/15 Received 190 195 141 34 40 19 Completed 188 245 161 18 41 40 - Successful 77 % 72 % 71 % 72 % 88 % 78 % Main reason for rejections and applications withdrawn by the applicant is errors in applications, the poor quality and/or unavailable data, including clinical, engineering, biomaterials and quality management system information
  • 9. Inclusion in the ARTG Applications for Inclusion: Medical Devices IVDs 2012/13 2013/14 2014/15 2012/13 2013/14 2014/15 Received 6500 (3700 assessed or audited) 6300 (3400 assessed or audited) 6100 (3600 assessed or audited) 550 640 720 Completed 5850 (3050) 6700 (3800) 5900 (3400) 520 610 650 - Successfully assessed or audited 88 % 87 % 89 % 85 % 91 % 90 % Applications for inclusion may be rejected or withdrawn due to incorrect classification, or if information is not available such as clinical evidence or information on conformity assessment procedures
  • 10. Post Market reviews Year ARTG entries reviewed Reviews completed Cancelled by sponsor Cancelled by TGA 2013 130 90 21 3 2014 226 168 34 13 Sponsor cancellations often due to device no longer being supplied, superseded, manufacturer / sponsor changes. TGA cancellations often due to non-response to s41JA requests for information, inability to certify matters, non-compliance with class I auto-inclusion conditions.
  • 11. Adverse event reports by class – 2014 245, 6% 1144, 26% 1757, 40% 480, 11% 35, 1% 291, 7% 7, 0% 38, 1% 77, 2% 253, 6% AIMD Class III Class IIb Class IIa Class 1 Sterile Class 1 For Class II, III and AIMD devices this is roughly proportional to the number of devices on the ARTG. Class I devices have few reports despite representing around half of all devices on the ARTG.
  • 12. Expert Panel Review of Medicine and Medical Device Regulation • Announced Oct 2014 to examine medicines and medical devices regulation “to identify areas of unnecessary, duplicative, or ineffective regulation and propose opportunities to enhance the regulatory framework” • First report on medicines and medical devices, provided to government on 31 March and second report on complementary medicines and advertising on 31 July 2015 • Devices stakeholder workshop run on 6 August 2015 • Next steps currently under consideration by the Government
  • 13. Overarching principles for regulation as recommended by the Expert Panel • Australia maintain the capacity to undertake assessments of therapeutic goods for safety, quality and efficacy • The Australian Government, as a sovereign entity, retain responsibility for approving the inclusion of therapeutic goods in the ARTG
  • 14. Some proposed initial reform bundles • Reforms to registration of New Chemical Entities • Reforms to generics and biosimilar medicines registration • Risk based approaches to variations of medicines on the ARTG • Reform to schemes for unapproved medicines and devices (i.e. the Special Access and Authorised Prescriber Schemes) • Establish criteria and mechanisms for expedited approval of (very) novel medical devices
  • 15. Review recommendations for Medical Devices (also apply to IVDs) • Multiple pathways are proposed for Class II, III, AIMD devices and Class 2–4 IVD products: – Conformity Assessment within Australia by either TGA or a separate body designated by TGA; OR – Utilisation of marketing approval for the device in an overseas market where the device has been:  Conformity Assessed by a body that has been designated by a comparable overseas Designating Authority; or  Approved by a comparable overseas regulatory authority • Expedited approval process for devices in some circumstances
  • 16. Much further consultation will be needed as implementation would be complex • Few commercial conformity assessment bodies currently exist in Australia • International device/ IVD regulatory frameworks are quite different to Australia and undergoing significant change, e.g. – New European Device and IVD Regulations – The US FDA system is very different - PMA vs 510(k), lack of clarity around laboratory developed IVD tests • Will need to define criteria and decision rights for expedited approval of devices • Approach to confidence building in notified bodies if there are to be fewer application audits
  • 17. Confidence building will require agreement TGA accepts Conformity Assessment certification from Notified Bodies, but highest risk devices currently have application audits ARTG = 48,000 device entries Highest risk devices (Class III and AIMD) = 4,300 Manufactured overseas= 4,250 (>98%) Over 80% of highest risk AIMDs/Class III devices are included on the ARTG with Conformity Assessment certification from six Notified Bodies: • BSI (UK) • TUV SUD (Germany) • LNE/G-MED (France) • Dekra (Netherlands) • Lloyds LRQA (UK) • Intertek (UK)
  • 18. Other device / IVD recommendations • Set binding timeframes for Conformity Assessment within Australia or for device inclusion using an international approval • Auto-inclusion of Class I devices to continue (unless if class 1 IVD selected for technical file review) • Streamline access to medicines and medical devices (including IVDs) that have not been approved in Australia – Some SAS Category B applications could be subject to automatic approval – Online system for SAS notifications, approvals and reporting
  • 19. Finally, a review of governance arrangements was proposed by the Panel • Comprehensive review of the legislative framework to simplify its structure and language • Review and enhance TGA’s funding model • Alternative decision making arrangements, including committees • Greater collaboration with HTA assessments (e.g. PBAC, MSAC)
  • 20. IVD regulatory framework • From 1990 to 2010 a limited number of IVDs were regulated in Australia including HIV and Hepatitis C virus (HCV) tests • In 2010 Australia introduced a more comprehensive regulatory framework for IVDs under the Therapeutic Goods (Medical Devices) Regulations 2002 • New framework covers both commercial and in-house (laboratory developed) IVDs but not research use only or analyte-specific reagents
  • 21. Some current IVD regulatory reforms…. • Amended definition of a medical device to include tests for predisposition and susceptibility to a disease • Modification to Classification for Class 3 IVDs that detect pathogens to remove reference to National Notifiable Disease Surveillance System list to instead use risk- based classification principles (some IVDs may be down classified to Class 2) • Timeframe for submission of applications for inclusion in the ARTG for commercial IVDs had been extended but is now over !
  • 22. International regulatory collaboration now a formal requirement by government “ if a system, service or product has been approved under a trusted international standard or risk assessment, then our regulators should not impose any additional requirements for approval in Australia, unless it can be demonstrated that there is a good reason to do so….. ……. As an important first step, the Government will enable Australian manufacturers of medical devices the option of using EU certification in place of TGA certification.” (media release 14 Oct 2014)
  • 23. • Aims to accelerate international device regulatory harmonisation and convergence • Established in 2012 to build on foundational work of GHTF (Global Harmonization Taskforce on Medical Devices) • Members: Australia, Brazil, Canada, China, EU, Japan, Russia and USA • Asian Harmonization Working Party and PAHO are affiliates and WHO and APEC are observers
  • 24. IMDRF Medical Device Single Audit Program Pilot from Jan 2014 for 3 years to: • Promote greater alignment of regulatory approaches and technical requirements • Develop a standard set of requirements for third party organisations performing audits of manufacturers’ QMS on behalf of regulators • Standardise oversight practices and procedures of participating regulators over third party auditing organisations, and the auditing organisations themselves • Enable TGA resources to be focused on problematic devices, manufacturers that are not in compliance with regulations, and oversight of third party auditors
  • 25. IMDRF Medical Device Single Audit Program Mid-pilot report released recently • Third party Canadian auditing organisation “registrars” assessed, undergoing MDSAP recognition requirements, comprehensive MDSAP QA system established • By end July 2015: several witnessed audits conducted, 10 audits of manufacturers conducted, 45 manufacturing sites requested participation in the MDSAP program • Initial progress is good – but greater manufacturer participation will be vital to success !
  • 26. Other IMDRF projects • Table of Contents pilot – Will develop a comprehensive submission structure as an international format for device premarket evaluation – Greater uniformity and reduced regional divergence will reduce burden on sponsors and increase efficiency of review – TGA current seeking applications from sponsors to trial • National Competent Authority Report review – Facilitates exchange of post market safety information • Software as a Medical Device – Definitions document, Framework for Risk Categorization – Harmonized vocabulary and considerations for manufacturers, regulators and users to address unique challenges with SaMD
  • 27. Other IMDRF projects Completed • Use of recognised Standards for devices to increase consistency • Roadmap for UDI implementation Recently initiated • Integrating Patient Registries and Innovative Tools for Enhanced Medical Device Evaluation and Tracking • Medical device adverse event terminology • Good regulatory review practice
  • 28. Draft medical device clinical assessment guidance documents • Developed as drafts together with ASERNIPS (Australian Safety and Efficacy Register of New Interventional Procedures – Surgical) • These guidance documents do not intend to change regulatory requirements but rather document the current situation • Purpose is to clarify approaches to assessment of clinical evidence for TGA evaluators, and help industry through providing consistent advice • No internationally accepted standards exist for clinical evidence for many types of devices, so much interest from IMDRF members • Consultation with PLAC, clinical craft groups and the device industry will be the next step
  • 29. Draft medical device clinical assessment guidance documents: content • General clinical evidence guidelines/ legislative requirements – clinical dossiers, evaluation report and evaluation of clinical data • Demonstrating substantial equivalence - guidance on use of clinical evidence from predicate devices • Guidance on specific high-risk device groups – Total and partial joint prostheses – Cardiovascular devices (that promote patency or functional flow) – Electrical impulse generators – Heart valve prostheses – Supportive devices – meshes, patches and tissue adhesives – Demonstrating MRI safety of active implantable medical devices (e.g. cardiac pacemakers)
  • 30. International inspection harmonisation • About 90 % of overseas inspections are avoided by TGA’s use of desktop clearances based on information provided by other regulators • International collaboration also includes: – joint inspections with overseas partners – Involvement in MDSAP – shared inspection scheduling – sharing of information, reports and manufacturer information – mutual recognition of codes and standards
  • 31. Navigating the regulatory maze • Australian regulatory guidelines for medical devices – all 330 pages of it …. • Currently developing simplified web linked guidance…. • Device hotline: 1800 141 144 or email devices@tga.gov.au • SME workshops and contact points are under consideration
  • 32. Subscribe to the TGA information services to stay up-to-date: www.tga.gov.au Receive information on: • Safety alerts • Recall actions • Medical Devices Safety Update • Consultations • Publications More specific information • Therapeutic Goods Act 1989 (especially Chapter 4) • Therapeutic Goods (Medical Devices) Regulations 2002 • Australian Regulatory Guidelines for Medical Devices
  • 33. TGA Business Improvement Program • Continue to enable electronic submissions for device regulatory processes • Strengthened guidelines and supporting information for sponsors and manufacturers • Centralised data repository – single source of data a client relationship management system • New client self-service portal for sponsors and manufacturers to − check application status − receive invoices − respond to requests for information
  • 34. Development underway of a new application form for conformity assessment certificates • Industry working group identified ways to improve the application form: – See only what is applicable to your application – Pre-population of information the TGA already has – Guides the applicant with the information required – Ability for TGA to push the form back to the client for more information – Access to TGA issued CA certificates within the application – Clear explanations and examples to assist with providing information BIP Conformity Assessment Workflow tool • Being further developed to remove problem issues – Will support the CA process through: a CA Application eForm, workflow automation for the administrative process, a CA Certificate Repository and Reporting Capability • In 2016 work will commence on integrating other device business processes into BIP, but will depend on changes to regulation that flow out of the MMDR
  • 35. Regulator Performance Framework (from July 2015) • Encourages regulators to have the minimum impact necessary to achieve objectives and to effect positive ongoing and lasting change • Six KPIs articulate the Government's expectations: – Regulators do not unnecessarily impede the efficient operation of regulated entities – Communication with regulated entities is clear, targeted and effective – Actions undertaken by regulators are proportionate to risk managed – Compliance and monitoring approaches are streamlined and coordinated – Regulators are open and transparent in dealing with regulated entities – Regulators actively contribute to continuous improvement of the regulatory framework • KPIs are supported by measures of good regulatory performance
  • 36. Next steps for regulatory reform • The MMDR recommendations (if accepted by Government) will provide an opportunity to implement many welcome changes • Government consideration of recommendations still to take place • Once Government decisions on the proposed reforms are known, implementation planning will be firmed up • We need to agree a governance plan and timeline, resource allocation, and the roles and responsibilities of different parts of TGA • Reforms outside the Expert Panel Review continue (e.g. business process reforms, in-house IVDs, Business Improvement Program) • But today’s sessions are about the current regulatory framework !